Quin Wills (L) and Jack O’Meara
A UK biotech looks to upset the preclinical model for liver drug development, and now it's gearing up for the clinic
Liver disease is one of the hardest therapeutic areas to hit, and some researchers have pointed to a dearth of meaningful preclinical models during drug development. Now, a UK biotech has figured out a workaround for its own siRNA liver drugs, and it all starts with discarded human organs.
Ochre Bio announced the closing of a $9.6 million seed financing round, led by Khosla Ventures. Backed VC, Apollo Health Ventures, Selvedge, Hoton and Hermes Epitek also participated in the fundraising.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters